Hester Biosciences Ltd (HESTERBIO) is currently trading at 2,347.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Hester Biosciences is a leading Indian animal healthcare company that manufactures poultry and large animal vaccines, markets over 50 vaccines and 70-plus health products, and operates manufacturing units in India, Nepal and Africa while distributing complementary pharmaceuticals, feed supplements and disinfectants across domestic and export markets. Q1 FY27 standalone results showed notable operating leverage: revenue grew ~14% year-on-year while PAT rose ~88%, gross margin expanded from 69% to 78% and EBITDA nearly doubled, driven by a favorable product mix, stronger poultry institutional business and operational efficiencies reflecting early traction from recent strategic initiatives. Consolidated revenue declined ~8% in Q1 FY27 due to weak Nepal and Africa receipts, but corporate reported an exceptional accounting gain after the Gates Foundation restructured Hester Africa’s soft loan from USD 12 million to USD 5 million with interest waived, materially improving near-term consolidated profitability and reflecting partner support in difficult regions. Operationally, Hester completed substantial manufacturing investments including a BSL3 facility and fill-and-finish capacity; management reports plant utilization around 60–65 percent, indicating meaningful spare capacity to absorb growth without immediate fresh capex, and management expects gradual utilization improvement as new veterinary and animal health products gain market traction.

Over the past 52 weeks, Hester Biosciences Ltd has traded between a low of ₹1,250.95 and a high of ₹2,669.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Hester Biosciences Ltd has a market capitalization of approximately 2,058.28. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Hester Biosciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 14.37 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,058.28 Cr, Hester Biosciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Hester Biosciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Hester Biosciences Ltd is 14.37. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Hester Biosciences reported standalone profit after tax of Rs 16.660 crore for the quarter ended 30 September 2026. The figure was 131.1% higher than Rs 7.209 crore in the quarter ended 30 September 2025. EPS increased to Rs 19.59 from Rs 8.48.

Hester Biosciences recorded the gain after HBAL’s Gates Foundation loan amendment was classified as a substantial modification under Ind AS 109. The revised cash flows differed by more than 10% in present-value terms from the original liability, requiring extinguishment of the old liability and recognition of a new one at fair value.

Hester Biosciences Limited reported consolidated net profit of Rs 96.73 crore for the quarter ended June 2026. This was 459% higher than Rs 17.30 crore reported in Q1 FY26.

Consolidated net profit for Q1 FY27 was ₹97 crore, compared with ₹16.4 crore in Q1 FY26.